People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies showed ...
A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...
Minerva Neurosciences Inc (NASDAQ:NERV) shares are climbing Tuesday after the company announced up to $200 million in funding ...
(NEW YORK) — From a pig kidney transplant to restoring genetic deafness, 2024 was a year full of medical breakthroughs. The breakthroughs include the discovery of a cause of an autoimmune disease, the ...
The FDA has approved Cobenfy, the first new schizophrenia treatment in over 30 years. Cobenfy helps reduce both positive and negative schizophrenia symptoms, with side effects compared to current ...
Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires ...
Schizophrenia affects how a person thinks, feels and behaves, and can cause paranoia, delusions, hallucinations, and changes in emotions, movements and behavior. Those symptoms can disrupt a patient's ...
Shares of Minerva Neurosciences surged more than fourfold after the company said it has secured up to $200 million in financing to advance an investigational schizophrenia treatment through a phase 3 ...
Many drugs are available for schizophrenia, but insufficient efficacy and intolerable side effects leave an unmet need that biotech companies are still trying to fill. LB Pharmaceuticals is not ...
The Food and Drug Administration on Thursday approved Bristol Myers Squibb's highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental ...